Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-31
2008-08-12
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S358100, C548S360100, C548S361100, C548S361500, C514S403000
Reexamination Certificate
active
07410992
ABSTRACT:
This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans, or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof: formula (II) represents C6-10aryl or C3-10heterocyclyl, said aryl or heterocyclyl optionally substituted with 1-3 groups selected from Ra; Z represents (CH2)nPO(OR)(OR*).
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5573758 (1996-11-01), Adorante et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5925342 (1999-07-01), Adorante et al.
patent: 7196082 (2007-03-01), Doherty et al.
patent: 1114816 (2001-07-01), None
patent: WO 89/10757 (1989-11-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 94/28900 (1994-12-01), None
patent: WO 96/33719 (1996-10-01), None
patent: WO 01/46140 (2001-06-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 01/72268 (2001-10-01), None
patent: WO 02/24647 (2002-03-01), None
patent: WO 02/42268 (2002-05-01), None
patent: WO 2004/085431 (2004-10-01), None
A. M. Harman et al., “Development and Aging of Cell Topography in the Human Retinal Pigment Epithelium”, 1997, pp. 2016-2026, vol. 38, No. 10, Investigative Ophthalmology & Visual Science.
E. L. Eliel et al., “Chirality in Molecules Devoid of Chiral Centers”, 1994, pp. 1119-1190, Chap. 14,Stereochemistry of Organic Compounds.
S. M. Berge et al., “Pharmaceutical Salts”, 1977, pp. 1-19, vol. 66, No. 1, J. of Pharmaceutical Sciences.
H. E et al., “New Antifungal 1,2,4-Triazoles with Difluoro (heteroaryl) methyl Moiety”, 2000, pp. 982-990, vol. 48, No. 7, Chem. Pharm. Bull.
O. P. Hamill et al., “Improved Patch Claim Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches”, 1981, pp. 82-100, vol. 391, Pflugers Archiv.
Chen Meng Hsin
Doherty James B.
Liu Luping
Natarajan Swaminathan
Tynebor Robert M.
Ayler Sylvia A.
Krovatini William
Merck & Co. , Inc.
Shameem Golam M
LandOfFree
Ophthalmic compositions for treating ocular hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic compositions for treating ocular hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic compositions for treating ocular hypertension will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015895